Stoke Therapeutics, Inc.
STOK· Nasdaq
Released Mar 18, 2025, before the open
10-K filed Mar 18, 2025, 77 days after period end · 0000950170-25-041170
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $22.61M | $2.80M | $3.27M | — |
| Net Income | -$10.48M |
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR
| -$26.96M |
| -$25.66M |
| -$24.45M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.